against PD-L1 Never 4/38 (10.5) 2/14 (14.3) (Abcam®) Smokers had significantly higher expression Wang 2015 [8] Preliminary: Prospective / Abstract NR All rates than non-smokers (67.0% vs. 44.0%, 0.039 NR p=0.039) NR Smoker 19/26 (73.1)d 18/26 (69.2) Konishi 2004 [9] Preliminary: Prospective >11% NS Anti-B7-H1 (MIH1) Non-smoker 7/26 (26.9)d 8/26 (30.8) Histology Epidermal growth factor receptor tyrosine kinase inhibitor PD-L1: rabbit Adenocarcinoma 52/59 (88.1) 30/46 (65.2) polyclonal antibody D'Incecco Staining intensity in more than 5% of ≥2 Preliminary: Retrospective 0.005 ab58810 (Abcam®) Squamous cell 2015 [6] tumor cells was considered as positive 7/59 (11.9) 16/46 (34.8) PD-1: 760–4448 carcinoma (Ventana) Adenocarcinoma 96/112 (85.7) 49/58 (84.5) 0.83 16/112 (14.3) 9/58 (15.5) Rabbit monoclonal Tang 2015 [2] Preliminary: Consecutive >5% Adenocarcinoma; anti-human antibody 32/96 (33.3) 24/49 (41.4) EGFR wild type 0.067 Adenocarcinoma; 64/96 (66.7) 25/49 (43.1) EGFRm+ Chemotherapy/radiotherapy Squamous 48 (28%)c E1L3N®, Schmidt 2015 [5] Preliminary: Retrospective >5% 0.089 #13684 rabbit IgG Non-squamous 29 (20%)c
against PD-L1 (Abcam®) Never 4/38 (10.5) 2/14 (14.3) Wang 2015 [8] Preliminary: Prospective / Abstract NR All Smokers had significantly higher expression rates than non-smokers (67.0% vs. 44.0%, p=0.039) 0.039 NR NR Konishi 2004 [9] Preliminary: Prospective >11% Smoker 19/26 (73.1)d 18/26 (69.2) NS Anti-B7-H1 (MIH1) Non-smoker 7/26 (26.9)d 8/26 (30.8) Histology Epidermal growth factor receptor tyrosine kinase inhibitor D'Incecco 2015 [6] Preliminary: Retrospective Staining intensity ≥2 in more than 5% of tumor cells was considered as positive Adenocarcinoma 52/59 (88.1) 30/46 (65.2) 0.005 PD-L1: rabbit polyclonal antibody ab58810 (Abcam®) PD-1: 760–4448 (Ventana) Squamous cell carcinoma 7/59 (11.9) 16/46 (34.8) Tang 2015 [2] Preliminary: Consecutive >5% Adenocarcinoma 96/112 (85.7) 49/58 (84.5) 0.83 Rabbit monoclonal anti-human antibody 16/112 (14.3) 9/58 (15.5) Adenocarcinoma; EGFR wild type 32/96 (33.3) 24/49 (41.4) 0.067 Adenocarcinoma; EGFRm+ 64/96 (66.7) 25/49 (43.1) Chemotherapy/radiotherapy Schmidt 2015 [5] Preliminary: Retrospective >5% Squamous 48 (28%)c 0.089 E1L3N®, #13684 rabbit IgG Non-squamous 29 (20%)c
1-s2.0-S0169500217304440-mmc1.docx